All posts by imreal

Strategic Radiology Adds First Oregon Practice, Diagnostic Imaging Northwest


Diagnostic Imaging Northwest

Phillip Baker, MD, PhD, President, Diagnostic Imaging Northwest

Our philosophy of practice is to be an active and valued participant in our communities and the institutions where we provide care. We think that membership in Strategic Radiology and the SR–Patient Safety Organization will help us continue to put the patient and referring physician first.

Diagnostic Imaging Northwest (DINW) has aligned with Strategic Radiology’s coalition of independent private radiology practices, bringing the current number of members to 27 and bolstering the organization’s presence in the Northwest. The group includes 12 subspecialty-trained radiologists.

“We are pleased to be welcoming Diagnostic Imaging Northwest into the Strategic Radiology coalition of independent practices,” said Arl Van Moore Jr, MD, FACR, CEO and chair, Strategic Radiology. “The practice brings a combination of excellent, quality-minded radiologists, a demonstrated willingness to collaborate, and a commitment to Strategic Radiology’s core values.”

DINW was founded nearly 100 years ago and during the past century has built a strong relationship with Legacy Health’s Good Samaritan Hospital, a leading subspecialty hospital In Portland with an oncology center operated in partnership with Oregon Health & Science University. It also provides subspecialty coverage for Skyline Hospital, in White Salmon, Washington.

The practice’s radiologists serve as department medical directors at both hospital sites and provide diagnostic mammography and breast biopsy for a new breast center operated by Women’s Health Associates, a 100-physician group of primarily OB-GYN physicians.

“Our philosophy of practice is to be an active and valued participant in our communities and the institutions where we provide care,” said Phillip D. Baker, MD, PhD, president, DINW. “We think that membership in Strategic Radiology and the SR–Patient Safety Organization will help us continue to put the patient and referring physician first.”

DINW is a partner in Legacy Health Partners, an accountable care organization with more than 2,500 physician members. The practice has been an integral member of the Portland health care provider community since the 1920s, introducing Oregon’s first CT scanner and first dedicated breast imaging center, both at Legacy Good Samaritan.

About Strategic Radiology

Strategic Radiology is a coalition of independent, private radiology practices, representing more than 1,100 radiologists. The coalition’s goal is to achieve higher quality patient care and more cost-efficient delivery of medical imaging through an integrated approach of shared data and best practices, interchanging clinical expertise, and consolidating certain practice expenses. It operates the nation’s only radiology-focused Patient Safety Organization listed by the Agency for Healthcare Research and Quality. http://www.StrategicRadiology.org.

SR Members:


  • Asheville Radiology Associates; Asheville, NC
  • Casper Medical Imaging and Outpatient Radiology; Casper, WY
  • Central Illinois Radiological Associates; Peoria, IL
  • Diagnostic Imaging Northwest; Portland, OR
  • Gaston Radiology; Gastonia, NC
  • The Hill Medical Corporation; Pasadena, CA
  • Huron Valley Radiology; Ann Arbor, MI
  • Inland Imaging; Spokane, WA
  • Mecklenburg Radiology Associates; Charlotte, NC
  • Medical Center Radiology Group; Orlando, FL
  • Minneapolis Radiology Associates; Minneapolis, MN
  • Modesto Radiological Medical Group (MRMG); Modesto, CA
  • Mountain Medical Physician Specialists; Salt Lake City, UT
  • Naugatuck Valley Radiological Associates; Waterbury, CT
  • Northwest Radiology; Indianapolis, IN
  • Quantum Radiology; Atlanta, GA
  • Radiologic Medical Services; Iowa City, IA
  • Radiology Associates; Jeffersonville, IN
  • Radiology Associates of Macon; Macon, GA
  • Radiology Associates of North Texas; Dallas/Fort Worth, TX
  • Radiology Associates of Tallahassee; Tallahassee, FL
  • Rome Radiology Group; Rome, GA
  • Southeast Radiology, Ltd.; Glen Mills, PA
  • Tower Imaging Medical Group; Santa Monica, CA
  • United Imaging Consultants; Mission, KS
  • University Radiology; East Brunswick, NJ
  • X-Ray Consultants; South Bend, IN

Share article on social media or email:

Catalent Announces Supplying Blueprint Medicines’ Precision Therapy AYVAKIT™ (avapritinib)


We thank the entire Catalent Nottingham team for their continued support these past four years in helping us rapidly develop this important advancement in precision therapy and make a significant difference for patients with high medical needs.

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, welcomes the announcement by Blueprint Medicines Corporation that the U.S. Food and Drug Administration (FDA) has approved AYVAKIT™ (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

Catalent’s Nottingham U.K. facility has supported Blueprint Medicines’ development program since 2015, from formulation development, clinical product supply and now commercial supply of AYVAKIT.

“We are delighted to help support Blueprint Medicines with commercial supply for this important medicine, recently approved by the FDA, which provides a new treatment option for patients with this disease,” commented Jonathan Arnold, President of Oral and Specialty Delivery at Catalent. “We have built a global network of development and clinical and commercial supply centers with the specific skills and expertise to help innovators like Blueprint Medicines meet challenging milestones for important novel therapies such as this.”

Jeff Albers, Chief Executive Officer of Blueprint Medicines, added, “We thank the entire Catalent Nottingham team for their continued support these past four years in helping us rapidly develop this important advancement in precision therapy and make a significant difference for patients with high medical needs.”

AYVAKIT and Blueprint Medicines are trademarks of Blueprint Medicines Corporation.

Please click here to see the full Prescribing Information for AYVAKIT.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

EnduRx Pharmaceuticals Awarded $1.4MM of a $1.75MM Grant to Collaborate with MD Anderson Cancer Center to Develop a Novel Therapeutic for Triple-negative Breast Cancer


EnduRx Pharmaceuticals, advancing a drug delivery system intended to improve outcomes for patients with hard-to-treat solid tumors, has been awarded $1.4 million dollar Department of Defense grant. The 36-month project is a collaboration with MD Anderson Cancer Center in Houston and will advance a novel therapeutic for triple-negative breast cancer to the point of pre-IND meeting with the FDA. Total project grant award is $1.75 million dollars.

“With triple-negative breast cancer, so-called because it lacks the receptors that enable the use of treatments employed for other forms of breast cancer, only about 30% of patients at best respond to standard-of-care treatment.” said Stephan Morris, MD, EnduRx Principal Investigator. “There are currently few approved drugs available specifically for the treatment of this fast growing and poor-outcome type of breast cancer. Untreated, the cancer is likely to metastasize to the brain and parts of the body, and the five-year survival rate is then only a little over 10%, so there is an urgent need for an effective therapy,” Morris said. “This form of breast cancer is diagnosed in about 10-20% of breast cancer patients, with an even higher proportion occurring in African-American women. We are pleased to have this opportunity to work with Dr. Naoto Ueno’s breast cancer group at MD Anderson, whose access to patient-derived xenograft models should provide a high level of confidence that the EnduRx Pharmaceuticals therapeutic candidate will translate well into human subjects with triple-negative breast cancer.”

About EnduRx Pharmaceuticals

EnduRx Pharmaceuticals Inc., a Tucson firm, is part of OBDURO Biotechnologies, a San-Diego company formed in 2019, to improve delivery of drugs selectively to the site of disease and not elsewhere in the body. In 2020 OBDURO plans a funding round and will use the proceeds to further leverage the grant-sponsored activities and generate persuasive data aimed at securing pharma partnerships. EnduRx previously received a $1.75 million SBIR grant to develop a prototype of the drug delivery system. “Earlier work showed tumor-volume reductions of over 90% in mouse models, with some cures. The DoD grant will allow EnduRx to complete pharmacokinetic and toxicology analyses as well as additional anti-cancer efficacy studies, data which are required before clinical trials can be initiated.” said David Loynd, Chief Executive Officer of OBDURO and EnduRx.

About the Congressionally Directed Medical Research Programs:

CDMRP was established in 1992 when Congress first appropriated funds targeted specifically for breast cancer research. Since that time, additional research programs and topics have been added by Congress, and CDMRP has evolved into a global funding organization that fosters novel approaches to biomedical research in response to the expressed needs of its stakeholders — the American public, the military, and Congress. For more information about CDMRP go to https://cdmrp.army.mil/. The views expressed in this article are those of the author and may not reflect the official policy or position of the Department of the Army, Department of Defense, or the U.S. Government.

For further information:

David Loynd, President & CEO

EnduRx Pharmaceuticals, Inc.

dloynd@endurxpharm.com

(855) 368-2878

Share article on social media or email:

Clean Air Gear’s New Product Eradicates Virus Particles


ViraKill-60 can inactivate airborne or surface virus particles

Clean Air Gear division of MicroSweep Corp. has introduced a novel new product that eradicates virus particles shed by a contagious person, whether they have symptoms or not. Virus particles are copies of the original virus that has been reproduced many-fold by an exhausted host-cell infection in a contagious person.

ViraKill-60 is a special type of portable air purifier that destroys virus particles using clean ozone, then neutralizes any remaining oxidant. Ozone will inactivate viruses on contact, even at very low residual concentrations. Ozone destroys viruses by diffusing through the protein coat into the nucleic acid core, resulting in damage to the viral RNA. Only 0.012 ppm of ozone removes all polio viral cells in less than 10 seconds.

The new ViraKill-60 (available at http://www.cleanairgear.com) creates temporary clean ozone that oxidizes viral particles on contact. Placed in a closed room and powered on, the unit cycles unattended for one hour. (The cleaning technology attacks organic molecules, including living cells, so the treatment area must be unoccupied while it cleans.) Treated premises can be reoccupied soon afterward because during the last ten minutes it neutralizes any ozone remaining in the treatment area. This is reliable because only clean ozone is produced, even in moist air, so there are no toxic byproducts to remove.

“ViraKill-60 can inactivate airborne or surface virus particles” said John Edwards, President of Clean Air Gear.

See ViraKill-60 at (http://www.cleanairgear.com) or email to info@virakill.com.

Clean Air Gear sells portable equipment to purify room air in the home and workplace.

Share article on social media or email:

Memorial Neuroscience Institute Performs Its First Robotic Brain Surgery to Help Ease Epileptic Seizures


“We are committed in adopting technology that is at the forefront of surgical treatments for epilepsy. The use of the robot will help the Memorial Neuroscience Institute to provide the cutting edge care to our patients.”

The epilepsy team at Memorial Neuroscience Institute successfully completed its first use of a minimally-invasive, robotic device that helps pinpoint the origin of epileptic seizures on a patient.

The device, now in full use at Memorial Regional Hospital, is called a Robotized Surgical Assistant, or ROSA. With assistance from the robot, neurosurgeons only need to make small, precise incisions in the scalp and skull to place electrodes deep in the brain and investigate where seizures are triggered.

The robot also improves accuracy, safety and can significantly reduce total surgery time, said Tarek Zakaria, MD, Medical Director for the Adult Neurology Program and Epilepsy Program.

By using the new technology, more data will be available to the epilepsy team to offer patients more advanced treatment options and help them to achieve their dreams to be seizure free, Zakaria said.

“We are committed in adopting technology that is at the forefront of surgical treatments for epilepsy,” Zakaria said. “The use of the robot will help the Memorial Neuroscience Institute to provide the cutting edge care to our patients.”

When medication is not enough to control seizures, neurosurgeons like Christopher DeMassi, MD and Daxa Patel, MD may take a surgical approach. That includes altering or removing brain tissue at the location where a patient’s seizures begin. However, they can only do so if they can first zero in exactly where that origin is. This is where Rosa can assist.

Recently, they performed the two-part procedure on a 24-year-old female patient, who began having epileptic seizures at age eight and had exhausted all available medications.

The procedure, called robot-assisted stereoelectroencephalography (SEEG), was performed as part of the services offered by the Memorial Neuroscience Institute Comprehensive Epilepsy Center.

“Our goal is to always bring in the latest innovative technologies to achieve the best possible outcome for our patients,” DeMassi said. “This is just the latest advancement available to the South Florida community and keeps us at the front of epilepsy care.”

Surgeons used ROSA and a 3-D reconstruction of the patient’s brain to guide them where to surgically implant electrodes without having to remove sections of her skull. DeMassi and Patel then used the robot’s arm to make two- or three-millimeter holes in the scalp through which the electrode wires were passed.

With the electrodes in place, Zakaria and his team were later able to see part of the patient’s brain “light up” on a computer monitor as a seizure began, essentially flagging the point of origin.

“Memorial Neuroscience Institute is proud to offer the most technologically advanced and comprehensive services for our patients and the community,” said Haroula Protopapadakis Nordem, FACHE, Associate Administrator at Memorial Regional Hospital.

“The addition of the ROSA to our program will allow our surgeons to deliver more precise results in a less invasive manner and allow our physicians to treat patients who otherwise might not have had a feasible treatment option,” she said.

Memorial’s epilepsy center is accredited by the National Association of Epilepsy Centers (NAEC) as a Level 4 program, a designation for programs offering the highest level of comprehensive and specialized care.

Memorial Regional Hospital in Hollywood, Fla., is one of the largest hospitals in Florida and is a facility of Memorial Healthcare System, one of the largest healthcare systems in Florida. Its wide scope of medical services and programs includes Memorial Cancer Institute, Breast Cancer Center, Cardiac and Vascular Institute, Neuroscience Center, Comprehensive Weight-Loss Surgery Program, Family Birthplace, Center for Behavioral Health, Sickle Cell Day Hospital, Women’s Services, Fitness and Rehabilitation Center, and a level I Trauma Center. For more information, visit memorialregional.com.

Share article on social media or email:

Next-generation Targeted Cytokine Therapy to be Explored on Advancements Series


News Image

“Deka’s platform has the potential to enable discoveries of next generation therapies,” said Richard Lubin.

An upcoming episode of Advancements with Ted Danson, scheduled to broadcast 2Q/2020, will explore innovative treatment solutions for maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn’s Disease (Crohn’s), and Oncology. Check local listings for more info.

This segment will focus on a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), that will enable the delivery of next generation cytokine or combination of cytokines to a specific tissue of interest. Viewers will learn how this cutting-edge technology, termed Diakines™, has led to the development of two potential therapeutic molecules involving an affinity modified Interleukin 10 cytokine.

The show will also explore how Deka Biosciences is using Diakines™ to harness the spectrum of therapeutically useful and clinically validated IL10 and other cytokine specific biologies. Spectators will see how these Diakines™ can maximize patient benefits through improved PK/PD function combined with a MOA directed patient selection strategy.

“The biopharma industry has known for a while that cytokines play an integral role in immunology and disease management, and that delivery of cytokine therapeutics into diseased tissues will dramatically enhance therapeutic benefit,” said Dr. John Mumm, co-founder & CEO of Deka Biosciences. He continued to say, “Deka Biosciences has harnessed the wealth of clinical knowledge around cytokines and IL-10 in particular, to develop a novel delivery platform to enrich cytokine variants in effected tissues, coupled with methods to determine how to select the patients with the greatest likelihood of response to ensure that the right patients get the right medicines.”

In addition, the show will also inform about Deka Biosciences’ Precision Medicine strategy, which enables Deka to identify the right patients to treat with these new medicines.

“Deka’s platform has the potential to enable discoveries of next generation therapies,” said Richard Lubin, senior producer for DMG Productions and the Advancements series. “We are eager to explore how Deka is set to influence future treatment options for IBD, Crohn’s.”

About Deka Biosciences:

Deka BioSciences, Inc., is an early-stage biotech focused on creating the next generation targeted cytokine therapies to treat chronic illnesses such as Crohn’s Disease and Oncology. Deka’s focus is on the development of optimized disease specific IL-10 variants coupled with the DiakinesTM T1/2 life extension tissue targeting technology. In parallel, Deka has developed a Precision Medicine strategy by identifying the genetic signature that drives responses to treatment to enable the selection of the patients most likely to benefit from our therapies.

About Advancements and DMG Productions:

The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.

Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.

For more information, please visit http://www.AdvancementsTV.com or call Richard Lubin at 866-496-4065.

Share article on social media or email:

Taxpayers Have Invested Billions In Electronic Health Records Systems


Doctors spend too much time away from patients because of burdensome technology and regulatory requirements.

New rules from the Department of Health & Human Services to give doctors more time with their patients may not perform as intended

In our view, improved patient access and experiences are relevant at the beginning of a patient’s care journey, when the decision whether or not to seek care is made. For patients, affordability has become a healthcare crisis. – Kevin Fleming, CEO, Loyale Healthcare

Just last week, the U.S. Department of Health and Human Services (HHS) released the final version of a comprehensive strategy developed jointly by the Centers for Medicare & Medicaid Services and the Office for the National Coordinator for Health Information Technology (ONC), following public comment solicited in late 2018. The document, “The Strategy on Reducing Regulatory and Administrative Burdens Relating to the Use of Health IT and EHRs (Electronic Healthcare systems)”, aims to apply the agencies’ rulemaking powers and considerable healthcare industry influence to “give clinicians more time to focus on what matters – caring for their patients.”

It is fair to say that everyone in the U.S. has an interest in the healthcare industry’s success improving the performance of their EHR systems – both as providers and patients. In research published nearly a year ago by Kaiser Health News and Fortune titled, “Death By 1,000 Clicks: Where Electronic Health Records Went Wrong.” The authors observed that “10 years after President Barak Obama signed a law to accelerate the digitization of medical records – with the federal government, so far, sinking $35 billion into the effort – American has little to show for its investment.”

The Fortune/KHN research goes on to state that “Rather than an electronic ecosystem of information, the nation’s thousands of EHRs largely remain a sprawling, disconnected patchwork. Moreover, the effort has handcuffed health providers to technology they mostly can‘t stand and has enriched and empowered the $13 -billion-a-year industry that sells it.”

Author, physician and CEO of Haven Healthcare Atul Gawande, also spoke to this issue in a New Yorker magazine article titled “Why Doctors Hate Their Computers” In it, Dr. Gawande asks “are screens coming between doctors and patients?” describing in detail the many negative outcomes for physicians and patients when doctors are required to interact with systems that were not designed to suit them or their work.

In an announcement from the Centers for Medicare and Medicaid Services (CMS) of the HHS strategy’s release, CMS administrator Seema Verna, noted that “The taxpayers made a massive investment in EHRs with the expectation that it would solve the many issues that plagued paper-bound health records. Unfortunately – as this report shows – the cure has been worse than the disease.” Ms. Verna went on to say that “it is unacceptable that the application of health IT still struggles to provider ready access to medical records, access that might mean the difference between life and death.”

HHS’s strategy report focuses on three primary goals, offering recommendations to:


  • Reduce the effort and time required to record information in EHRs for healthcare provider when they are seeing patients.
  • Reduce the effort and time required to meet regulatory reporting requirements of clinicians, hospitals and healthcare organizations; and
  • Improve the functionality and intuitiveness (ease of use) of EHRs


HHS’s strategy announcement has been met with a blend of optimism and skepticism. Healthcare providers and their agencies have complimented the agency’s attention to reducing excessive burden, a problem that is universally acknowledged among hospitals and other providers. However, in a comment published the day following the announcement, the American Hospital Association (AHA) stated that “some ONC recommendations…could have unintended consequences for adoption of current standards and would not address the lack of transparency or uniformity around payer requirements.”

The AHA went on to recommend that the agency “align Medicare and Medicaid clinician requirements in the Promoting Interoperability Program; improve its systems for attesting to meaningful use of EHRs (a condition for the above referenced federal funding); and improve its certification requirements.” The AHA also noted that “the lack of interoperability affects the usability of EHRs and urged the agencies to more forward with policies to support information exchange.”

As with any high-level strategy, the success of HHS’s proposal and the American healthcare industry’s effort to reduce the administrative and regulatory burdens on Health IT and EHR systems will depend on the details. Details that may be more complex and challenging than in any other sector of the American economy. When one considers the size of the industry ($3.3 Trillion, representing close to 20% of GDP), the scope and scale of this challenge makes sense.

Taking a Larger View of the Patient Journey

The EHR and Health IT problems facing healthcare are not confined to clinically-related functionality. They affect every other aspect of the patient’s experiences. In their respective statements, CMS Administrator Verner and Dr. Gawande point out how flaws in EHR and other Health IT systems can compromise patient safety. Often missed in this discussion, however, are other aspects of the patient’s care experience. Specifically, the financial dimension of care.

In an article published by Loyale Healthcare last year titled, “Electronic Medical Record Systems: Powerful for Clinical Engagement, A Liability for Patient Financial Engagement”, Loyale CEO Kevin Fleming focused not on the clinical deficiencies inherent to these disparate, overly complicated systems but to the financial and administrative obstacles they have placed between patients and their care. Mr. Fleming also noted how the massive investments of time, effort and money necessary to deploy and operate these systems often create organizational fatigue that blinds healthcare providers to other investments with the potential to improve the performance of their EHR to provide patients with better access and experiences.

In our view, improved patient access and experiences are relevant at the beginning of a patient’s care journey, when the decision whether or not to seek care is made. Astonishingly for more than half of Americans at that early stage, out-of-pocket costs are the deciding factor. According to research published late last year, 51% of survey respondents said that they had avoided care due to an inability to pay. 78% have been afraid to go to the hospital because of cost. For patients, affordability has become a healthcare crisis.

For many healthcare providers, affordability is synonymous with transparency; more specifically, the ability for patients to know what the cost for their care will be in advance, before treatment has begun. This issue was explored in greater detail in a more recent Loyale article examining another CMS initiative. Titled “Medicare’s Price Transparency Rules Alone Don’t Deliver What Patients Need – A Patient-First Approach Does.”

In this article, Mr. Fleming applauds CMS’s intentions. However, like the AHA’s criticism of the new HHS strategy to reduce EHR burdens, he notes that the rules themselves are inadequate for achieving their stated objectives. “CMS rules threaten to distract providers and payers from the larger, more important issue facing healthcare and patients. That issue is patient financial engagement.” To that end, five essential healthcare deliverables were described:

1.    Present upfront cost estimates for the anticipated course of treatment and all associated expenses, including pre-service eligibility so a reliable out-of-pocket estimate is also presented.

2.    Offer multiple payment options to address patient affordability. The Loyale Affordability Workbench, for example, offers provider-configured options that may include discounts for prompt or upfront payment; short-term interest free financing; or longer-term payment plans funded by third party lenders with a reputation for client care.

3.    Interactive self-service options with secure personalized experiences that measure up to the best online experiences consumers have with trusted brands like Amazon, Apple, Zappos and other industry leaders. This is the new standard by which providers will be measured.

4.    Personalized, contextual digital communications that honor each patient’s preferences and behavior. For some providers up until recently, every patient with an unpaid balance became little more than a number – a balance to be collected. In an industry dedicated to health and well-being, no provider can hope to compete without engaging in the financial dimension of care.

5.    End-to-end data analytics, so providers have the information they need to make evidence-based decisions about their patient-pay portfolios and manage for success – as care givers and as business operators.

Many of the same flaws affect both HHS’s new EHR Burden Reduction Strategy and CMS’s Price Transparency rules. Fortunately, the remedies for both are similar. The solution calls for developing a platform approach to healthcare’s operating model. An approach that incorporates multiple system inputs into a single, manageable whole. One that makes sense for provider-users and delights patients at the same time. At Loyale, we are confident our industry will succeed in hitting that mark.

Kevin Fleming is the CEO of Loyale Healthcare

About Loyale

Loyale Patient Financial Manager™ is a comprehensive patient financial engagement technology platform leveraging a suite of configurable solution components including predictive analytics, intelligent workflows, multiple patient financing vehicles, communications, payments, digital front doors and other key capabilities.

Loyale Healthcare is committed to a mission of turning patient responsibility into lasting loyalty for its healthcare provider customers. Based in Lafayette, California, Loyale and its leadership team bring 27 years of expertise delivering leading financial engagement solutions for complex business environments. Loyale currently serves approximately 12,000 healthcare providers across 48 states. Loyale is proud to be an enterprise-level strategic partner with Parallon, including deployment of Loyale’s industry leading technology to all HCA hospitals and Physician Groups.

Fauzia Khanani, Founder and Principal Architect at Studio Fōr, Named Co-Chair of The American Institute of Architects New York Social Science and Architecture Committee


News Image

The Social Science and Architecture Committee serves as a forum for thought leaders in architecture, anthropology, psychology, health care, hospitality, and real estate who are looking to understand how these fields can respond to design challenges of the future.

Fauzia Khanani, Principal Architect and Founder of Studio Fōr, an award-winning architecture and interior design practice based in New York City, was appointed Co-Chair of the American Institute of Architects (AIA) New York Social Science and Architecture Committee effective January 1, 2020. She will serve the two-year term with Co-Chair Eve Klein, an architect, strategic planner and doctoral candidate in Environmental Psychology advancing diversity and inclusion. Klein co-founded the committee in 2016 with outgoing Co-Chair Melissa Marsh, Founder of PLASTARC.

The committees of AIA New York are the foundations from which the Chapter positions itself in the field of architecture, whether through discussion, advocacy, policy making and development, event and exhibition planning, or other endeavors. Committees meet monthly, usually at the Center for Architecture. AIA members, AIA associate members, and the general public are all welcome to participate.

Since its founding, the Social Science and Architecture Committee at the AIANY chapter has brought together professionals and students from architecture and social science fields to discuss best practices and facilitate public programs. These meetings, workshops, think-tank dinners and panel discussions offer a place and time to exchange ideas related to social science and architecture collaborations, environmental design research, and other topics. 

Khanani has been an active member in the AIANY Social Science and Architecture Committee since the co-founders developed their idea in 2015. She has created programming, moderated panels and facilitated workshops. “Like my architecture practice, the committee is a place where my two degrees cross over,” says Khanani, who received a Master of Architecture degree from the University of California Berkeley after earning a B.A. in Sociology from the University of North Carolina at Chapel Hill.

She continues to be influenced by her previous career in social science research and public health, which has shaped how Studio Fōr approaches architecture. Using case studies, focus groups, surveys, and other in-depth social science research tools in the client-discovery phase of a project allows Studio Fōr to create innovative, well-informed designs that address functional and aesthetic client needs. An awareness of how materials, colors, light, and textures affect human behavior also helps her to create spaces that promote change, healing, and a sense of inspiration.

“We spend a significant amount of time in the initial stages of a project, getting to know our clients through in-depth research,” Khanani explains. “We want to know as much as we can about our clients, their goals and expectations, and what makes them unique, since this really influences the end product and ultimately affects their quality of life.”

Klein and Marsh say of the committee, “The Social Science and Architecture Committee serves as a forum for thought leaders in architecture, anthropology, psychology, health care, hospitality, and real estate who are looking to understand how these fields can respond to design challenges of the future. The Committee aims to remedy this disconnect by facilitating the development of stronger links between architecture and other fields of expertise that can inform better design.”

Share article on social media or email:

Ziegler Link-Age Academy, an expanded and improved version of our Demo Thursday Programming


“We are passionate about supporting our investors not only by generating financial returns, but by being catalysts for change and breaking new ground in advancing solutions for older adults,” stated, Dan Hermann, President and CEO and Head of Investment Banking at Ziegler.

The Ziegler Link•Age Funds are excited to announce the Ziegler Link-Age Academy, an expanded and improved version of our Demo Thursday Programming.

The Ziegler Link•Age Funds invest in early to mid-stage, emerging-growth companies that are operating in or developing businesses focused on either the aging or post-acute care markets. The investors in the funds consist primarily of organizations across the healthcare, senior living, and aging services landscape that have a significant interest in finding innovative solutions to improve the independence, quality and cost of care, and overall lives of the aging population.

Thus, the Ziegler Link•Age Funds have worked to facilitate collaboration amongst up-and-coming tech entrepreneurs in the space and the companies they hope will become their customers, by hosting periodic series of weekly, web-based demonstrations of new and interesting technologies that could be used in the context of a senior living community or other healthcare organizations.    With the release of the Ziegler Link-Age Academy, the program will continue to feature up-and-coming technology companies, but will add educational sessions, thought leadership and presentations from the funds’ portfolio companies.

Ziegler Link-Age Academy will now host webinars on Wednesdays with a target of 30 per year. The format will remain consistent with 25-35-minute presentation, followed by 15-20 minutes of Q&A. The events will remain exclusive to investors in the funds.

John Hopper, the Chief Investment Officer of the Funds, stated, “We have been pleased to present 99 different Demo Thursday presentations during the life of our funds. We have seen innovative companies and unique solutions so our investors can gain insight to what the future might look like for healthcare. With the new year, and feedback we have received we have made some enhancements to our program and our approach, and are excited to launch the Ziegler Link-Age Academy in March of 2020.”

Dan Hermann, President and CEO and Head of Investment Banking at Ziegler, stated, “Our Demo Thursday programs have helped our investors remain informed of the newest, most relevant technologies and services in an ever-changing healthcare landscape, while at the same time supporting growing companies reach their targeted customers. The Ziegler Link-Age Academy will build on this foundation to also provide research and perspectives on the latest challenges and opportunities facing our industry” Mr. Hermann continued, “We are passionate about supporting our investors not only by generating financial returns, but by being catalysts for change and breaking new ground in advancing solutions for older adults.”

About the Ziegler Link•Age Funds:

The Ziegler Link•Age Funds are a fund family consisting of two funds that seek to invest in companies who are improving aging and post-acute services in the United States and around the world. The funds, with over $60 million in assets, seek to invest in growth companies who are able to dramatically improve the healthcare IT or healthcare services landscape for our aging population. The Fund’s Limited Partners include many of the most innovative and progressive senior living providers, healthcare systems and strategic service providers in the United States, Canada and Australia. The funds are managed by a joint venture between Ziegler (http://www.ziegler.com) and Link•Age (http://www.LinkageConnect.com).

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the outcome of pending litigation and the ability to attract and retain qualified employees.

Share article on social media or email:

HME Experts Join Forces, Prepare Providers for 20% Medicare Pay Raise


The home medical equipment (HME) industry is changing. HME veterans Joey Graham and Ty Bello are preparing providers for this shift with their new white paper, “2021 & Beyond: From Surviving to Thriving.” Since 2003, providers have struggled under Medicare’s competitive bidding program; now, as 2021 rates take effect, experts project a 20% increase in revenues. Graham and Bello offer guidance so that providers can smartly invest their additional income for long-term success.

Graham and Bello’s recommendations are based on their decades of experience in HME billing, consultative, and executive roles. Their guidelines, which range from paying down high-interest debt and investing in your team to specializing and participating in industry events, aim to help providers operate their businesses better in a new, flourishing era.

“HME providers have operated in one way over the last 16 years: survival mode,” says Graham, the executive vice president and general manager at Prochant. He adds, “We can’t expect providers to thrive in our industry without guiding them through this important paradigm shift.”

Ty Bello, chief executive officer at Team@Work, LLC, agrees. He explains, “A successful HME industry works together for the greater good of its customers.” Bello continues, “By learning from the industry’s thought leaders, you gather the tools necessary to become a better provider.”

For Graham and Bello’s full list of recommendations, please download a copy of the white paper here: http://bit.ly/round2021. The content includes:


  • Overview of past industry struggles;
  • Outlook on future industry success;
  • Guidelines for success in a new era;
  • Tips to create a robust 2021 budget.

To learn more about Prochant’s HME billing services, please visit http://www.prochant.com or contact Sarah Tollie at marketing(at)prochant(dot)com. For more information about Team@Work’s coaching services, please visit http://www.teamatworkcoaching.com.

About Prochant

Prochant is the nation’s leading HME billing and process outsourcing company. Our highly skilled team helps providers become more profitable by outsourcing or enhancing existing front- and back-office processes. We rapidly implement changes and proactively monitor metrics to ensure client success. Headquartered in Charlotte, North Carolina, we work with top medical equipment providers and health systems. For more information, please visit http://www.prochant.com or follow us on LinkedIn and Twitter @prochant.

About Team@Work

Team@Work is a business and sales coaching organization. With over 30 years of HME experience, our team comes alongside of providers to grow top- and bottom-line revenue, while impacting change that is long lasting. For more information, please visit http://www.teamatworkcoaching.com or follow us on LinkedIn and Twitter @TAWCoaching.

Share article on social media or email: